[EN] NAPHTHRIDINE DERIVATIVES AS PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNE - INFLAMMATORY DISEASES [FR] DÉRIVÉS DE NAPHTRIDINE EN TANT QU'INHIBITEURS DE PI3K POUR LE TRAITEMENT DU CANCER ET DE MALADIES IMMUNO-INFLAMMATOIRES
[EN] NAPHTHRIDINE DERIVATIVES AS PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNE - INFLAMMATORY DISEASES<br/>[FR] DÉRIVÉS DE NAPHTRIDINE EN TANT QU'INHIBITEURS DE PI3K POUR LE TRAITEMENT DU CANCER ET DE MALADIES IMMUNO-INFLAMMATOIRES
申请人:KARUS THERAPEUTICS LTD
公开号:WO2011135351A1
公开(公告)日:2011-11-03
Compounds of formulae (I) and (II): or a pharmaceutically acceptable salt thereof, wherein: R1 is a nitrogen-containing 5 to 7-membered heteroaryl or heterocycle; R2 and R3 are each independently (LQ)mY, are described. The compounds are PI3K inhibitors and are useful for the treatment of cancer and immune-inflammatory diseases.
NAPHTHRIDINE DERIVATIVES AS PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNE - INFLAMMATORY DISEASES
申请人:Karus Therapeutics Limited
公开号:EP2563788A1
公开(公告)日:2013-03-06
NAPHTHRIDINE DERIVATIVES AS PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNE-INFLAMMATORY DISEASES
申请人:Karus Therapeutics Limited
公开号:EP2563788B1
公开(公告)日:2015-08-05
US9266879B2
申请人:——
公开号:US9266879B2
公开(公告)日:2016-02-23
Naphthridine derivatives as PI3K inhibitors for the treatment of cancer and immune-inflammatory disease
申请人:Shuttleworth Stephen Joseph
公开号:US20130109688A1
公开(公告)日:2013-05-02
Compounds of formulae (I) and (II): or a pharmaceutically acceptable salt thereof, wherein: R
1
is a nitrogen-containing 5 to 7-membered heteroaryl or heterocycle; R
2
and R
3
are each independently (LQ)
m
Y, are described. The compounds are PI3K inhibitors and are useful for the treatment of cancer and immune-inflammatory diseases.